Adicet Bio
ACET
94 hedge funds and large institutions have $90.4M invested in Adicet Bio in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 32 closing their positions.
0.45% less ownership
Funds ownership: 5.86% → 5.41% (-0.45%)
12% less funds holding
Funds holding: 107 → 94 (-13)
19% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 31
33% less call options, than puts
Call options by funds: $57K | Put options by funds: $85K
41% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 32
61% less capital invested
Capital invested by funds: $231M → $90.4M (-$141M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.46M |
| 2 |
O
OrbiMed
New York
|
+$4.83M |
| 3 |
Morgan Stanley
New York
|
+$4.46M |
| 4 |
Millennium Management
New York
|
+$3.36M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20.5M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$7.28M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$3.22M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.84M |
| 5 |
CAC
Cowen and Company
New York
|
-$1.7M |
ACET Hedge Fund Activity: Q2 2023 in Review
94 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2023, worth a combined $90.4M — down 61% from $231M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ACET and 19 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 25 added.
The largest buyer was Deutsche Bank, adding an estimated $5.46M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $20.5M sold.
- 94 institutional investors held Adicet Bio (ACET) as of Q2 2023, down from 107 in Q1 2023.
- Funds reported $90.4M of Adicet Bio stock for Q2 2023, down 61% quarter-over-quarter.
- 19 funds opened new Adicet Bio positions in Q2 2023 and 32 closed out, a net change of -13 holders.
- The largest Adicet Bio buyer in Q2 2023 was Deutsche Bank, an estimated $5.46M added.
- The largest Adicet Bio seller in Q2 2023 was EcoR1 Capital, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2023.